ArticleNature2025
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- PI(3,5)PScience advances · 2026Article
- A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.Cancer cell · 2026Article
- Propionyl-CoA catabolism is a metabolic gatekeeper for fatty acid oxidation in pancreatic cancer.Oncogene · 2026Article
- Metabolism, autophagy, and cell death: The triangular axis in tumor survival and therapeutic resistance.Redox biology · 2026Review
- Targeting PIKfyve: Chemical Biology and Drug Discovery Insights.Chemical biology & drug design · 2026Review
- The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.Biochemical Society transactions · 2026Review
- Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer.Signal transduction and targeted therapy · 2026Review
- Article
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- Targeting lysosome-dependent cell death in cancer: towards therapeutic strategies.Biomarker research · 2026Review
- Immune-Metabolic Profiling Reveals Functional Heterogeneity Within Colorectal Cancer Consensus Molecular Subtypes.Biology · 2026Article
- A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Lysosomal lipid metabolism promotes tumor cell invasion through local energetics and membrane lipid remodeling.bioRxiv : the preprint server for biology · 2026Article
- Nutrient stress-induced FTH1 safeguards redox balance and fuels pancreatic ductal adenocarcinoma growth while serving as a therapeutic target and diagnostic biomarker.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The OAS1-FASN axis promotes pancreatic cancer by coordinating lipogenic stress and the unfolded protein response.Cell death & disease · 2026Article
- The Lysosome-Cathepsin Axis in Pancreatic Cancer: Mechanisms of Stromal Remodeling, Immune Evasion, and Therapy Resistance.Biomolecules · 2026Review
- Integrated genomic, transcriptomic, and metabolomic profile analysis reveals molecular mechanism underlying meat quality traits in Chinese Kangle chickens.Food chemistry. Molecular sciences · 2026Article
- A PI(3,5)PNature communications · 2026Article
- Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Communications biology · 2026Article
- PIKfyve preserves endolysosomal function in photoreceptors and RPE cells to maintain retinal integrity.Cell death & disease · 2026Article
Corrections and comments
- Update of
Authors and funding
33 authors.
Caleb ChengMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1872-2661
Jing HuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7604-6732
Rahul MannanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6642-0468
Tongchen HeMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Rupam BhattacharyyaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-4292-2372
Brian MagnusonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Jasmine P WisniewskiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0005-1481-6478
Sydney PetersMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Saadia A KarimCRUK Scotland Institute, Glasgow, UK.ORCID 0000-0002-3727-0667
David J MacLeanCRUK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4932-2839
Hüseyin KarabürkDepartment of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-3458-9445
Li ZhangDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
Nicholas J RossiterCellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7333-1546
Yang ZhengMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6793-3206
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Chungen LiState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Beijing, People's Republic of China.
Dominik AwadDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-7386-2061
Somnath MahapatraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Yi BaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Yuping ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8727-5183
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Zhen WangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Beijing, People's Republic of China.ORCID 0000-0001-8762-6089
Rohit MehraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6955-8884
Pietro MorlacchiAgilent Technologies, Lexington, MA, USA.
Vaibhav SahaiRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1892-1548
Marina Pasca di MaglianoRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Yatrik M ShahDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-2487-4816
Lois S WeismanDepartment of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7740-9785
Jennifer P MortonCRUK Scotland Institute, Glasgow, UK.ORCID 0000-0001-5766-9141
Ke DingState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Beijing, People's Republic of China.
Yuanyuan QiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. qiaoy@med.umich.edu.ORCID 0000-0002-1178-3480
Costas A LyssiotisDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA. clyssiot@umich.edu.ORCID 0000-0001-9309-6141
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@med.umich.edu.ORCID 0000-0001-9282-3415
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2MMICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6MTumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5MExploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4MMichigan-VUMC Biomarker Characterization CenterU2CCA271854 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jeffrey John Tosoian · 2022 to 2026
$5.4MThe role of HIF2alpha in colon carcinogenesisR01CA148828 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2010 to 2025
$5.2MFibroblast orchestration of the immune response in pancreatic cancerU01CA274154 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Howard C. Crawford, Timothy Louis Frankel · 2022 to 2026
$4.2MCellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1MIntratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic CancerR37CA237421 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Costas Andreas Lyssiotis · 2020 to 2026
$2.6MRegulation of parallel recycling pathways at synaptic sitesR01NS129198 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Michael Mark Alexander Sutton, Lois S Weisman · 2022 to 2026
$2.4MUnderstanding the mechanisms of iron addiction in colon cancerR01CA245546 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2020 to 2024
$2.3MNCI NIH HHS F30 CA288093NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA148828NCI NIH HHS R01 CA244931NCI NIH HHS R01 CA245546NCI NIH HHS R01 CA248160NCI NIH HHS R35 CA231996NCI NIH HHS R37 CA237421NCI NIH HHS U01 CA274154NCI NIH HHS U2C CA271854NCI NIH HHS U54 CA274371NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM145470NIGMS NIH HHS T32 GM150581NINDS NIH HHS R01 NS129198
Abstract
Pancreatic ductal adenocarcinoma (PDAC) subsists in a nutrient-deregulated microenvironment, making it particularly susceptible to treatments that interfere with cancer metabolism
Indexed as
Carcinoma, Pancreatic DuctalLipid MetabolismMolecular Targeted TherapyPancreatic NeoplasmsPhosphoinositide-3 Kinase InhibitorsAnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionFemaleHumansMaleMAP Kinase Signaling SystemMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPIKFYVE protein, humanPikfyve protein, mouseProto-Oncogene Proteins p21(ras)
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.